Nuvalent, Inc. (NUVL)
Jul 15, 2026 - NUVL was delisted (reason: acquired by GSK)
123.96
+0.02 (0.02%)
Inactive · Last trade price on Jul 14, 2026
Nuvalent Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 159.73 | 261.75 | 145.69 | 335.39 | 241.81 | 68.53 |
Short-Term Investments | 1,128 | 1,110 | 972.61 | 384.52 | 230.36 | 219.59 |
Cash & Short-Term Investments | 1,287 | 1,372 | 1,118 | 719.91 | 472.16 | 288.11 |
Cash Growth | 19.96% | 22.68% | 55.34% | 52.47% | 63.88% | 2688.53% |
Prepaid Expenses | 20.46 | 20.47 | 14.15 | 6.58 | 5.83 | 2.52 |
Total Current Assets | 1,308 | 1,392 | 1,132 | 726.49 | 477.99 | 290.63 |
Other Long-Term Assets | 23.21 | 20.28 | 9.3 | 5.9 | 4.47 | 3.2 |
Total Assets | 1,331 | 1,413 | 1,142 | 732.38 | 482.46 | 293.82 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 22.14 | 30.16 | 5.23 | 9.27 | 7.2 | 2.89 |
Accrued Expenses | 58.92 | 61.01 | 48.8 | 22.55 | 12.29 | 5.89 |
Total Current Liabilities | 81.05 | 91.17 | 54.02 | 31.82 | 19.48 | 8.79 |
Other Long-Term Liabilities | 75.73 | 73.2 | 17.94 | - | - | - |
Total Liabilities | 156.78 | 164.37 | 71.96 | 31.82 | 19.48 | 8.79 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 2,257 | 2,218 | 1,617 | 986.82 | 623.54 | 363.48 |
Retained Earnings | -1,082 | -972.43 | -547.05 | -286.3 | -160.08 | -78.22 |
Comprehensive Income & Other | -1.36 | 2.35 | -0.06 | 0.03 | -0.49 | -0.23 |
Total Common Equity | 1,174 | 1,248 | 1,070 | 700.56 | 462.98 | 285.04 |
Shareholders' Equity | 1,174 | 1,248 | 1,070 | 700.56 | 462.98 | 285.04 |
Total Liabilities & Equity | 1,331 | 1,413 | 1,142 | 732.38 | 482.46 | 293.82 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 1,287 | 1,372 | 1,118 | 719.91 | 472.16 | 288.11 |
Net Cash Growth | 19.96% | 22.68% | 55.34% | 52.47% | 63.88% | 3458.24% |
Net Cash Per Share | 17.29 | 18.87 | 16.84 | 12.36 | 9.51 | 13.23 |
Filing Date Shares Outstanding | 79 | 78.62 | 71.6 | 64.07 | 56.7 | 48.31 |
Total Common Shares Outstanding | 78.88 | 78.24 | 71.34 | 64.07 | 56.67 | 48.3 |
Working Capital | 1,227 | 1,301 | 1,078 | 694.67 | 458.51 | 281.84 |
Book Value Per Share | 14.89 | 15.96 | 14.99 | 10.94 | 8.17 | 5.90 |
Tangible Book Value | 1,174 | 1,248 | 1,070 | 700.56 | 462.98 | 285.04 |
Tangible Book Value Per Share | 14.89 | 15.96 | 14.99 | 10.94 | 8.17 | 5.90 |